Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Significant Decline in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 54,700 shares, a decline of 31.5% from the October 15th total of 79,900 shares. Based on an average trading volume of 181,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 4.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Stock Performance

Shares of NASDAQ:SNOA traded down $0.02 during trading on Friday, hitting $2.56. The company’s stock had a trading volume of 15,310 shares, compared to its average volume of 159,561. The company has a market capitalization of $3.43 million, a PE ratio of -0.51 and a beta of 1.38. Sonoma Pharmaceuticals has a fifty-two week low of $2.52 and a fifty-two week high of $9.37. The stock’s 50-day moving average price is $3.08 and its two-hundred day moving average price is $1.35.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.